Cancer Cell International-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2022-04-26 章晓风

偏重的研究方向：肿瘤;Cancer
经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津

54 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2022-03-03 ms1000000289565013

偏重的研究方向：肿瘤;细胞生物学
经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。

51 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2021-01-26 kurisuly

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：EBV;PATHWAY;CANCER
经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。

91 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2023-02-07 tangshicong 来自上海

审稿速度:24.0 | 投稿命中率:75.0
偏重的研究方向：乳腺癌
经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。

40 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2023-08-21 宝塔镇河妖来自北京

我一直卡在 Editor appointed 咋回事呀

30 16

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2022-05-28 大内泌探

审稿速度:12.0
经验分享：绷不住了审稿审了小半年

59 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2023-04-07 ms1000001361403109 来自吉林省

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：消化道肿瘤
经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下

37 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2023-05-28 666's tom 来自上海

收到一篇lncRNA HAGLR的审稿

45 0

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2023-04-03 投稿中来自江苏省

偏重的研究方向：肿瘤
经验分享：胰腺癌内质网应激？binchen

28 0

[GetPortalCommentsPageByObjectIdResponse(id=1214367, encodeId=1099121436e25, content=偏重的研究方向：肿瘤;Cancer 经验分享：我的二审修回1个月了，都还是reviewers invited，有没有小伙伴能指点迷津, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/31/acd275c8ee710a029c1f67cc80ff2472.jpg, createdBy=28492314309, createdName=章晓风, createdTime=Tue Apr 26 00:13:08 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198917, encodeId=5e2f119891e60, content=偏重的研究方向：肿瘤;细胞生物学 经验分享：2021-11-15投稿，2022-03-01接收，两个审稿人提出了十几条意见，认真回复了，让补实验没有补，后来修回以后审稿人没有意见了又找了第三个审稿人，让补实验没有补，小修回去接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ad95447046, createdName=ms1000000289565013, createdTime=Thu Mar 03 01:04:38 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920000, encodeId=06b292000074, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：EBV;PATHWAY;CANCER 经验分享：10.20投稿，10.21editor assigned,10.22under review,11.28major revisions,12.28修回，1.3editor assigned，1.5under review，1.8minor revisions，1.18修回，1.19revision complete，1.21editor assigned，1.25accept。总用时3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f2c5455992, createdName=kurisuly, createdTime=Tue Jan 26 14:25:08 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2113339, encodeId=68042113339d9, content=审稿速度:24.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌 经验分享：太慢了。2021年10月4日投稿，2022年10月18日大修,11月18日修回，2023年1月25日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af391636253, createdName=tangshicong, createdTime=Tue Feb 07 00:45:57 CST 2023, time=2023-02-07, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153882, encodeId=189e215388236, content=我一直卡在 Editor appointed 咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2abb5505391, createdName=宝塔镇河妖, createdTime=Mon Aug 21 15:48:35 CST 2023, time=2023-08-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1223051, encodeId=33c11223051f9, content=审稿速度:12.0 经验分享：绷不住了审稿审了小半年, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fd0b2467870, createdName=大内泌探, createdTime=Sat May 28 22:29:03 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124325, encodeId=75da2124325b5, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：消化道肿瘤 经验分享：写了篇综述投稿2周了，还没有消息，打算在满一个月的时候催一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88438132359, createdName=ms1000001361403109, createdTime=Fri Apr 07 18:59:56 CST 2023, time=2023-04-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2139500, encodeId=153c213950002, content=收到一篇lncRNA HAGLR的审稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=69cb5422782, createdName=666's tom, createdTime=Sun May 28 12:53:10 CST 2023, time=2023-05-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2123492, encodeId=819f212349250, content=偏重的研究方向：肿瘤 经验分享：胰腺癌内质网应激？binchen, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqNZjGy4w5YZ0nnUWYokllg4nOIU4USYQniaUH0BCPrjHqwia1BLT0JTsKs9TO48UI8buibYsgVlVZ1w/132, createdBy=47272002716, createdName=投稿中, createdTime=Mon Apr 03 15:57:23 CST 2023, time=2023-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223112, encodeId=debc12231120d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210222/80bdeec0f3f34445aac0344bb5d0ca22/eafe07d5604f4c0a85d42d0f35be2184.jpg, createdBy=2ae15443834, createdName=小白先生, createdTime=Sun May 29 10:24:29 CST 2022, time=2022-05-29, status=1, ipAttribution=)]

2022-05-29 小白先生

审稿速度:3.0 | 投稿命中率:50.0
经验分享：纯生信不收了，投稿第三天分配编辑后拒稿，给的建议是加入细胞/动物实验以验证其生物学功能，加入实验后建议我重新投，在cover letter注明这次分配的文章ID号，总的来说编辑还是很负责的哦！

83 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务